

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL	
OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

Report for the Calendar Year or Quarter Ended: 09-30-2021

Check here if Amendment X Amendment Number: 1

This Amendment (Check only one.): X is a restatement.
 adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: JOHNSON & JOHNSON
Address: ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933

Form 13F File Number: 028-20072

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: Matthew Orlando
Title: Secretary
Phone: 732-524-2455

Signature, Place, and Date of Signing:

/s/ Matthew Orlando New Brunswick, NJ 11-16-2021
[Signature] [City, State] [Date]

This amendment is being filed solely to include Johnson & Johnson UK Treasury Company Limited as an Included Manager and to indicate in the Information Table that a previously-reported position is held by this Manager.

Report Type (Check only one.):

X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)

13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)

13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page

Report Summary:

Number of Other Included Managers: 2
Form 13F Information Table Entry Total: 25
Form 13F Information Table Value Total: 1,139,968
(thousands)

List of Other Included Managers:

Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

No.	Form 13F File Number	Name
1	028-20073	Johnson & Johnson Innovation - JJDC, Inc.
2		Johnson & Johnson UK Treasury Company Limited

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL	
OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5	COLUMN 6	COLUMN 7	COLUMN 8	
			VALUE	SHRS OR	SH/ PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x\$1000)	PRN AMT	PRN CALL	DISCRETION	MANAGER	SOLE SHARED NONE
ADICET BIO, INC.	COM	007002108	5,715	728,944	SH	DFND	1	0 728,944 0
ALDEYRA THERAPEUTICS, INC.	COM	01438T106	3,467	394,834	SH	DFND	1	0 394,834 0
ARROWHEAD PHARMACEUTICALS	COM	04280A100	203,576	3,260,869	SH	DFND	1	0 3,260,869 0
BIOMX INC.	COM	09090D103	6,528	2,133,402	SH	DFND	1	0 2,133,402 0
CASTLIGHT HEALTH INC.	CL B	14862Q100	1,274	811,295	SH	DFND	1	0 811,295 0
CATALYST BIOSCIENCES, INC.	COM	14888D208	275	66,951	SH	DFND	1	0 66,951 0
CUE HEALTH, INC.	COM	229790100	65,532	5,548,864	SH	DFND	1	0 5,548,864 0
CVRX, INC.	COM	126638105	57,817	3,495,575	SH	DFND	1	0 3,495,575 0
FATE THERAPEUTICS, INC.	COM	31189P102	200,277	3,379,064	SH	DFND	1	0 3,379,064 0
FUSION PHARMACEUTICALS INC.	COM	36118A100	29,070	3,670,516	SH	DFND	1	0 3,670,516 0
GRAYBUG VISION, INC.	COM SHS	38942Q103	164	49,547	SH	DFND	1	0 49,547 0
LEGEND BIOTECH CORPORATION	SPONSORED ADS	52490G102	82,371	1,629,173	SH	DFND	1	0 1,629,173 0
MEIRAGTX HOLDINGS PLC	COM	G59665102	38,203	2,898,550	SH	DFND	1	0 2,898,550 0
NEUROPACE, INC.	COM	641288105	879	55,435	SH	DFND	1	0 55,435 0
PHASEBIO PHARMACEUTICALS, INC.	COM	717224109	4,998	1,607,044	SH	DFND	1	0 1,607,044 0
POINT BIOPHARMA GLOBAL INC.	COM	730541109	7,690	1,000,000	SH	DFND	1	0 1,000,000 0
PROCEPT BIOROBOTICS CORPORATION	COM	74276L105	38,855	1,018,478	SH	DFND	1	0 1,018,478 0
PROTAGONIST THERAPEUTICS INC.	COM	74366E102	43,400	2,449,183	SH	DFND	1	0 2,449,183 0
PULMONX CORPORATION	COM	745848101	203	5,639	SH	DFND	1	0 5,639 0
SENSEONICS HOLDINGS, INC.	COM	81727U105	185	54,621	SH	DFND	1	0 54,621 0
TRACON PHARMACEUTICALS, INC.	COM	89237H209	325	84,003	SH	DFND	1	0 84,003 0
VOR BIOPHARMA, INC.	COM	929033108	16,851	1,074,658	SH	DFND	1	0 1,074,658 0
ZYMERGEN INC.	COM	98985X100	218	16,553	SH	DFND	1	0 16,553 0
ILLUMINA, INC.	COM	452327109	328,613	810,170	SH	DFND	2	0 810,170 0

SOMALOGIC, INC.

COM

83444K105 3,482

281,052 SH

DFND

N/A

0

281,052 0